

Fig. 1A




Fig. 1B




Fig. 1C




Fig. 1D




Fig. 1E




Fig. 1F




Fig. 2 BEST AVAILABLE COPY




Fig. 3A




Fig. 3B




Fig. 3C




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 4E




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 5D




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 6D




Fig. 6E

G0/G1 = 57%S = 20%G2/M = 22%800 Medium Curcumin-treated alok12701.002 alok12701.004 G0/G1 = 56%G0/G1 = 52%S = 21% S = 22%G2/M = 23%Counts 80 120 G2/M = 25%1000 800 FL2-A FL2-A alck12701.006 alok12701.008 G0/G1 = 59% G0/G1 = 54% S = 19%S = 20%G2/M = 22%Counts 80 120 G2/M = 25%1000 600 800 alok12701.010 alok12701.012 G0/G1 = 61% G0/G1 = 70%S = 20%S = 9%G2/M = 18%Counts 80 120 G2/M = 20%800 1000 500 1000

FL2-A

Untreated

alok12701,001

0 h

6 h

12 h

24 h

\$

Fig. 7

FL2-A




Fig. 8A





Fig. 8C



BEST AVAILABLE COPY

Fig. 8B




Fig. 9





Fig. 10A

BEST AVAILABLE COPY



BEST AVAILABLE COPY

Fig. 10B





Fig. 11A

EMSA KBM5 + TNF MM

Patient #4


◆ NF-κB

Fig. 11B



BEST AVAILABLE COPY

Fig. 12A



BEST AVAILABLE COPY

Fig. 12B






Fig. 12C



BEST AVAILABLE COPY



BEST AVAILABLE COPY




Fig. 14A




Fig. 14B




Fig. 14C





Fig. 14D

Patient #20 None Curcumin Dexamethason

NF-κB (p65)

Fig. 15A



BEST AVAILABLE COPY

Fig. 15B




Fig. 16A




Fig. 16B